Drug Profile
Monoclonal antibody prost 30
Latest Information Update: 17 Nov 2003
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 17 Nov 2003 Discontinued - Phase-II for Prostate cancer in USA (IV-injection)
- 11 Mar 2002 No development reported - Phase-II for Prostate cancer in USA (IV-injection)
- 11 Sep 1997 Phase-II clinical trials for Prostate cancer in USA (IV-injection)